Cargando…

Functional and molecular characterization of PD1(+) tumor-infiltrating lymphocytes from lung cancer patients

Antibody-mediated cancer immunotherapy targets inhibitory surface molecules, such as PD1, PD-L1, and CTLA-4, aiming to re-invigorate dysfunctional T cells. We purified and characterized tumor-infiltrating lymphocytes (TILs) and their patient-matched non-tumor counterparts from treatment-naïve NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipp, Jesse J., Wang, Limei, Yang, Haitang, Yao, Feng, Harrer, Nathalie, Müller, Stefan, Berezowska, Sabina, Dorn, Patrick, Marti, Thomas M., Schmid, Ralph A., Hegedüs, Belazs, Souabni, Abdallah, Carotta, Sebastian, Pearson, Mark A., Sommergruber, Wolfgang, Kocher, Greg J., Hall, Sean R.R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837234/ https://www.ncbi.nlm.nih.gov/pubmed/35154905 http://dx.doi.org/10.1080/2162402X.2021.2019466

Ejemplares similares

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Wang, Limei, et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2022)

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
por: Xu, Duo, et al.
Publicado: (2019)

Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model
por: Bichsel, Colette A., et al.
Publicado: (2017)

Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis
por: Xu, Duo, et al.
Publicado: (2021)

Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer
por: Liang, S-Q, et al.
Publicado: (2015)

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2023)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022)

Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung—A Single Center Analysis of 354 Cases
por: Neppl, Christina, et al.
Publicado: (2019)

The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
por: Zens, Philipp, et al.
Publicado: (2022)

Fibrosierte Hypersensitivitätspneumonie: Fokus auf pathologierelevante Aspekte der neuen klinischen Leitlinie der ATS/JRS/ALAT zur Diagnostik der Hypersensitivitätspneumonie bei Erwachsenen
por: Berezowska, Sabina
Publicado: (2020)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

Update Thoraxpathologie 2020: Bericht der Arbeitsgemeinschaft
por: Petersen, Iver, et al.
Publicado: (2020)

Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: Yang, Haitang, et al.
Publicado: (2020)

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
por: Yang, Zhang, et al.
Publicado: (2021)

Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy
por: Losmanova, Tereza, et al.
Publicado: (2021)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas
por: Langer, Rupert, et al.
Publicado: (2018)

Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
por: Fischhaber, Natalie, et al.
Publicado: (2023)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity
por: Yang, Haitang, et al.
Publicado: (2020)

The Relationship Between Periodontal Disease (Pd) and Cardiovascular Disease (Cvd).
por: Trevisan, Maurizio, et al.
Publicado: (2010)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Frequency and Significance of Pathologic Pulmonary Findings in Postmortem Examinations—A Single Center Experience before COVID-19
por: Berezowska, Sabina, et al.
Publicado: (2021)

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
por: Carotta, Sebastian
Publicado: (2016)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Update Thoraxpathologie 2021 – Bericht der Arbeitsgemeinschaft
por: Berezowska, Sabina, et al.
Publicado: (2021)

HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
por: Hegedűs, Luca, et al.
Publicado: (2020)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration
por: Watt, Jennifer, et al.
Publicado: (2013)

Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients
por: Zhang, Tuo, et al.
Publicado: (2021)

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
por: Buisseret, Laurence, et al.
Publicado: (2016)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
por: Yoshida, Kazushige, et al.
Publicado: (2020)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Colonic metastasis from infiltrating ductal breast carcinoma in a male patient: A case report
por: Jones, Ashley, et al.
Publicado: (2018)

Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
por: Däster, Silvio, et al.
Publicado: (2020)

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
por: Angell, H. K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gds9susc85la3ctaj6ifggju9m